Vilaro Inhalation Capsule 25 mcg + 62.5 mcg is a combination bronchodilator formulation containing Vilanterol Trifenatate and Umeclidinium Bromide. It is intended for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This dual-acting inhalation therapy improves lung function, reduces symptoms, and enhances overall respiratory comfort.

Vilaro works by combining two complementary mechanisms of action: a long-acting beta₂-agonist (LABA) and a long-acting muscarinic antagonist (LAMA). Together, they provide sustained bronchodilation, helping patients breathe more easily throughout the day.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Long-acting bronchodilator combination (LABA + LAMA)

Indications

Vilaro Inhalation Capsule is indicated for:

• Maintenance treatment of airflow limitation in patients with chronic obstructive pulmonary disease (COPD)

• Long-term management of chronic bronchitis and emphysema

• Reduction of COPD-related symptoms such as breathlessness and wheezing

• Improvement of exercise tolerance and quality of life in COPD patients

This product is not indicated for the relief of acute bronchospasm or for the treatment of asthma.

Pharmacology

Vilanterol Trifenatate is a long-acting beta₂-adrenergic agonist that relaxes bronchial smooth muscle by stimulating beta₂ receptors in the lungs. This leads to prolonged bronchodilation and improved airflow.

Umeclidinium Bromide is a long-acting muscarinic antagonist that inhibits the action of acetylcholine on M3 receptors in airway smooth muscle. This prevents bronchoconstriction and further enhances airway relaxation.

The combined action of these two agents provides superior bronchodilation compared to either component alone, resulting in better symptom control and sustained improvement in lung function.

Dosage and Administration

• Recommended dose: One inhalation capsule once daily, administered using a suitable dry powder inhaler device

• The capsule is for inhalation use only and must not be swallowed

• Patients should use the medication at the same time each day for optimal benefit

Dosage adjustments are generally not required unless advised by a healthcare professional.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

Vilaro Inhalation Capsule is contraindicated in patients with:

• Known hypersensitivity to vilanterol, umeclidinium, or any component of the formulation

• Severe milk protein allergy (if lactose-containing excipients are present)

• Acute episodes of bronchospasm requiring immediate relief

Side Effects

Common side effects may include:

• Nasopharyngitis

• Cough

• Headache

• Dry mouth

• Upper respiratory tract infections

Less common but serious adverse effects may include:

• Palpitations or tachycardia

• Urinary retention

• Increased intraocular pressure

• Paradoxical bronchospasm

Patients should seek medical attention if severe or persistent adverse effects occur.

Precautions and Warnings

• Not intended for acute symptom relief

• Use with caution in patients with cardiovascular disorders, glaucoma, or prostatic hyperplasia

• Patients should be instructed on proper inhalation technique

• LABA-containing medicines should not be used more frequently than prescribed

Pregnancy and Lactation

• Pregnancy: Use only if the potential benefit justifies the potential risk

• Lactation: Caution is advised; consult a healthcare professional before use

Storage Conditions

Store in a cool and dry place.
Protect from moisture and heat.
Keep out of reach of children.